Primary HIV-1 Drug-Resistant Minority Variants.
Primary HIV drug-resistant mutations are mutations that occur in an HIV-infected individual prior to the initiation of antiretroviral therapy. These mutations may arise by de novo mutagenesis or result from transmission. Drug-resistant mutations may reduce the effectiveness of antiretroviral therapy...
| Publicado en: | AIDS Reviews Vol. 19; no. 2; pp. 89 - 97 |
|---|---|
| Autores principales: | , , , |
| Formato: | Artículo |
| Publicado: |
Publicidad Permanyer SLU
Apr-Jun2017
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=124008503&site=ehost-live header: @attributes: shortDbName: lth uiTerm: 124008503 longDbName: MedicLatina uiTag: AN controlInfo: bkinfo: jinfo: jid: 11396121 3PWJ jtl: AIDS Reviews issn: 11396121 maglogo: N pubinfo: dt: Apr-Jun2017 vid: 19 iid: 2 pid: 37650 pub: Publicidad Permanyer SLU artinfo: ui: 124008503 ppf: 89 ppct: 8 formats: fmt: @attributes: type: P size: 953KB tig: atl: Primary HIV-1 Drug-Resistant Minority Variants. aug: au: Chimukangara, Benjamin Samuel, Reshmi Naidoo, Kogieleum de Oliveira, Tulio affil: Africa Centre for Population Health, Doris Duke Medical Research Institute, Nelson Mandela School of Medicine, University of KwaZulu-Natal Department of Virology, National Health Laboratory Service, University of KwaZulu-Natal Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal South African Medical Research Council (SAMRC)-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit. Durban, South Africa su: HIV infections Therapeutics Antiretroviral agents Genetic mutation Drug resistance in microorganisms Drug efficacy sug: subj: HIV infections Therapeutics Antiretroviral agents Genetic mutation Drug resistance in microorganisms Drug efficacy keyword: Antiretroviral therapy Minority variant Next generation sequencing Primary drug resistance ab: Primary HIV drug-resistant mutations are mutations that occur in an HIV-infected individual prior to the initiation of antiretroviral therapy. These mutations may arise by de novo mutagenesis or result from transmission. Drug-resistant mutations may reduce the effectiveness of antiretroviral therapy, leading to inadequate virological outcomes. Currently, Sanger sequencing is the standard method for detection of drug-resistant mutations to inform treatment decisions, but it does not detect minor variant mutations. Drug-resistant minority variants can be detected by next generation sequencing. However, several challenges, including cost of infrastructure and the need for complex data analysis bioinformatics tools, remain major setbacks for next generation sequencing use. More importantly, the clinical impact of drugresistant minority variants on antiretroviral therapy is not well understood, underscoring the importance for understanding whether the levels of primary drug-resistant minority variants for different mutations impact on the effectiveness of antiretroviral therapy and the rationale for inclusion in routine diagnostics. Understanding the impact of primary drug-resistant minority variants will help inform how next generation sequencing may be utilized in the future for pre-emptive clinical antiretroviral therapy decision making. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: Y custom: Copyright of AIDS Reviews is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. item: AIDS Reviews holder: Publicidad Permanyer SLU dt: @attributes: year: 2017 holdings: @attributes: islocal: N |
|---|